nothing new in the report that hasn't been announced already
but certainly makes for positive reading:
- Test modifications have delivered favourable results
o Modified test patterns improve response time
o Target pH levels are close to being achieved
o New oxidant is delivering results
o Uranium in recovery solution increases
Uranium sales activities forecast to secure net cash margin of US$8 million to US$9 million
in CY2022 (that's on top of the $6M-$8M it will receive from uranium sales this year)
It's nice to be receiving incoming revenue and not doing capital raises like the other U companies have done in the past week-months. Unfortunately, CRs can't be avoided because the explorers/developers have no source of incoming revenue.